Aevi Genomic Medicine, Inc. (GNMX)

[hedge_fun]

Under the terms of the License Agreement, the Company has exclusive license rights for the worldwide development and commercialization of Astellas’ second generation mTORC1/2 inhibitor, ASP7486 (OSI-027) (individually, an “ OSI Product ” and collectively, the “ OSI Products ”). Pursuant to the terms of the Royalty Agreement, in exchange for a one-time aggregate payment of $2,000,000 (the “ Purchase Price ”) made by the Investors to the Company, the Company will pay to the Investors, on a quarterly basis during the term of the Royalty Agreement, an aggregate amount equal to a low-single digit percentage of the aggregate net sales of the OSI Products for such quarter (the “ Royalty Amount ”). The Royalty Amount will be paid to each Investor based on such Investor’s pro rata percentage of the Purchase Price. At any time beginning three years after the date of the first public launch of an OSI Product (the “ Buyout Payment Date ”), the Company may exercise, at its sole discretion, a buyout option that terminates the Company’s further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments (as determined by a mutually agreeable independent valuation firm) otherwise likely to be due under the Royalty Agreement from the Buyout Payment Date through the later of the end of data regulatory exclusivity and the date upon which the last of the patents relating to the OSI Products expire.

https://ih.advfn.com/stock-market/NASDAQ/aevi-genomic-medicine-inc-GNMX/stock-news/80365916/current-report-filing-8-k